<DOC>
	<DOCNO>NCT00949182</DOCNO>
	<brief_summary>RATIONALE : Sorafenib tosylate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , doxorubicin hydrochloride mitomycin C , work different way stop growth tumor cell , either kill cell stop dividing . Chemoembolization kill tumor cell carry drug directly tumor block blood flow tumor . Giving sorafenib tosylate chemoembolization may kill tumor cell . PURPOSE : This phase II trial study side effect well give sorafenib tosylate hepatic arterial chemoembolization doxorubicin hydrochloride mitomycin C work treat patient localize liver cancer remove surgery .</brief_summary>
	<brief_title>Sorafenib Tosylate Before After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride Mitomycin C Treating Patients With Localized Liver Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate safety tolerability sorafenib tosylate therapy administer doxorubicin hydrochloride-based hepatic arterial chemoembolization ( HACE ) assess NCI CTCAE v3.0 patient localize unresectable hepatocellular carcinoma . Secondary - To determine sorafenib tosylate decrease number HACE treatment require achieve radiologic tumor kill . - To assess improvement progression-free survival . - To assess change monthly AFP level patient AFP-producing tumor . - To measure VEGF level . OUTLINE : Patients receive oral sorafenib tosylate twice daily day 1-14 . Beginning ≥ 3 day later , patient undergo hepatic arterial chemoembolization ( HACE ) * doxorubicin hydrochloride mitomycin C. Beginning ≥ 3 day completion HACE and/or liver function return baseline , patient resume sorafenib tosylate twice daily 6 month absence disease progression unacceptable toxicity . NOTE : *Patients may undergo one HACE treatment . Blood sample collect periodically laboratory analysis .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Inclusion Criteria Age &gt; 18 year old Confirmed HCC diagnosis Biopsy Radiologic parameter . Following NCCN guideline HACE , include subject within University San Francisco transplant list criterion . ECOG Performance Status 0 1 Adequate bone marrow , liver renal function .assessed follow : Hemoglobin &gt; 9.0 g/dl Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Platelet count &gt; 75,000/mm3 Total bilirubin &lt; 2 mg/dl ALT AST &lt; 2.5 time ULN ( &lt; 5 x ULN patient liver involvement ) Creatinine &lt; 1.5 time mg/dl Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment Women childbearing potential men must agree use adequate contraception ( barrier method birth control ) prior study entry duration study participation . Men use adequate birth control least three month last administration sorafenib . Ability understand willingness sign write informed consent . A sign informed consent must obtain prior study specific procedure . INR &lt; 1.5 PT/PTT within normal limit . Patients receive anticoagulation treatment agent warfarin heparin may allow participate . For patient warfarin , INR measure prior initiation sorafenib monitor least weekly , define local standard care , INR stable . BCLC Stage B ( Intermediate ) multinodular asymptomatic tumor without vascular invasion without extrahepatic spread Child Pugh A B7 Male female patient &gt; 18 year age Life expectancy least 12 week . Patients unresectable , multinodular asymptomatic tumor ( vascular invasion extrahepatic spread ) Patients histologically cytologically document HCC . Documentation original biopsy diagnosis acceptable tumor tissue unavailable Prior inform consent . At least one tumor lesion meet follow criterion : The lesion accurately measure least one dimension accord RECIST The lesion previously treat local therapy ( surgery , radiation therapy , RFA , PEI , cryoablation ) Exclusion Criteria Cardiac disease : Congestive heart failure &gt; class II NYHA . Patients must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month . Known brain metastasis CNS disease . Patients neurological symptom must undergo CT scan/MRI brain exclude brain metastasis . Cardiac ventricular arrhythmia require antiarrhythmic therapy . Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management . Known human immunodeficiency virus ( HIV ) infection Active clinically serious infection &gt; CTCAE Grade 2 except hepatitis B C. Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . Pulmonary hemorrhage/bleeding event &gt; CTCAE Grade 2 within 4 week first dose study drug . Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week first dose study drug . Serious nonhealing wound , ulcer , bone fracture . Evidence history bleed diathesis coagulopathy Major surgery , open biopsy significant traumatic injury within 4 week first study drug . Use St. John 's Wort rifampin ( rifampicin ) . Known suspected allergy sorafenib agent give course trial . Any condition impair patient 's ability swallow whole pill . Any malabsorption problem . Use prior systemic chemotherapy target agent . Diffuse HCC presence vascular invasion ( include segmental portal obstruction ) , extrahepatic spread Advanced liver disease : unstable ascites &gt; ChildPugh B7 Portosystemic shunt Any contraindication arterial procedure impair clot test ( platelet count &lt; 50.000/mm3 prothrombin activity &lt; 50 percent ) , 1 Renal failure Severe atheromatosis Any contraindication systemic chemotherapy administration ( serum bilirubin &gt; 5mg/dL , leukocyte count &lt; 3.000 cells/mm3 ) Any contraindication sorafenib administration Patients clinically significant gastrointestinal bleeding within 30 day prior study entry Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result Pregnant breastfeed patient Previous concurrent cancer distinct primary site histology HCC , EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis &amp; T1 ) . Any cancer curatively treat &gt; 3 year prior entry permit Patients receive therapy Hepatitis A , B C Encephalopathy ≥ Grade 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
</DOC>